AES and Science 37 Partner to Provide Virtual Trial Access
Accelerated Enrollment Solutions and Science 37 are collaborating to recruit and enroll clinical trial participants who live beyond the geographic location of traditional research sites. The collaboration enables AES to provide its customers with increased patient access by reaching beyond its existing, physical site infrastructure of more than 180 research sites. The companies also are working to rapidly deliver continuity solutions for clinical trials affected by the COVID-19 pandemic.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
